Search review questions

Risk for at least one adverse event per patient · patients with cholestatic pruritus (CP)

Pruritus: significant improvement · patients with cholestatic pruritus (CP)

Pruritus · patients with cholestatic pruritus (CP)

Quality of life · patients with cholestatic pruritus (CP)

Patient satisfaction ‐ not measured · patients with cholestatic pruritus (CP)

Pruritus · patients with chronic kidney disease (CKD) pruritus

Depression ‐ not measured · patients with cholestatic pruritus (CP)

Risk for at least one adverse event per patient ‐ not measured · patients with cholestatic pruritus (CP)

Quality of life ‐ not reported · patients with chronic kidney disease (CKD) pruritus

Patient satisfaction ‐ not reported · patients with chronic kidney disease (CKD) pruritus

Depression ‐ not reported · patients with chronic kidney disease (CKD) pruritus

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Adverse events (reported in the first 7 days after the procedure) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Serious adverse events (defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016)) · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain relief ‐ as reported by the child ‐ defined as proportion of participants with ≥ 50% postoperative pain relief in each treatment arm, 2 hours to less than 24 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Pain intensity – as reported by the child, less than 2 hours postintervention · children aged 17 years or younger treated for acute postoperative or postprocedural pain

Quality of life FACT‐G (scale from 0 to 108; higher score = better QoL) · adults aged 18 years and older receiving palliative care

Survival Log‐rank analysis Study enrolment to last date of · adults aged 18 years and older receiving palliative care

Adverse events NRS (scale from 0 to 10; lower score = less toxicity) · adults aged 18 years and older receiving palliative care

Quality of life · adults aged 18 years and older receiving palliative care

Survival Cox regression model Study enrolment to last date of · adults aged 18 years and older receiving palliative care

Adverse events Participant events · adults aged 18 years and older receiving palliative care

Pain reactivity (first 30 seconds post‐procedure) · preterm born neonates

Pain reactivity (first 30 seconds post‐procedure) · preterm born neonates

Immediate pain regulation (between 30 seconds and 5 minutes post‐procedure) · preterm born neonates

Adverse events · preterm born neonates

Pain reactivity (first 30 seconds post‐procedure) · full‐term born older infants

Immediate pain regulation (between 30 seconds and 5 minutes post‐procedure) · full‐term born older infants

Adverse events · full‐term born older infants

Immediate pain regulation (between 30 seconds and 5 minutes post‐procedure) · preterm born neonates

Adverse events · preterm born neonates